vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and COMSCORE, INC. (SCOR). Click either name above to swap in a different company.
COMSCORE, INC. is the larger business by last-quarter revenue ($93.5M vs $86.8M, roughly 1.1× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -1.5%). COMSCORE, INC. produced more free cash flow last quarter ($2.9M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 3.8%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
IOVA vs SCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $93.5M |
| Net Profit | — | $3.0M |
| Gross Margin | 67.4% | 41.0% |
| Operating Margin | -84.7% | 7.0% |
| Net Margin | — | 3.2% |
| Revenue YoY | 17.7% | -1.5% |
| Net Profit YoY | — | -3.7% |
| EPS (diluted) | — | $9.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $93.5M | ||
| Q3 25 | $67.5M | $88.9M | ||
| Q2 25 | $60.0M | $89.4M | ||
| Q1 25 | $49.3M | $85.7M | ||
| Q4 24 | $73.7M | $94.9M | ||
| Q3 24 | $58.6M | $88.5M | ||
| Q2 24 | $31.1M | $85.8M | ||
| Q1 24 | $715.0K | $86.8M |
| Q4 25 | — | $3.0M | ||
| Q3 25 | $-91.3M | $453.0K | ||
| Q2 25 | $-111.7M | $-9.5M | ||
| Q1 25 | $-116.2M | $-4.0M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | $-83.5M | $-60.6M | ||
| Q2 24 | $-97.1M | $-1.7M | ||
| Q1 24 | $-113.0M | $-1.1M |
| Q4 25 | 67.4% | 41.0% | ||
| Q3 25 | 43.0% | 40.6% | ||
| Q2 25 | 5.5% | 40.6% | ||
| Q1 25 | -0.8% | 39.6% | ||
| Q4 24 | 68.7% | 42.4% | ||
| Q3 24 | 46.2% | 41.2% | ||
| Q2 24 | -0.8% | 39.5% | ||
| Q1 24 | — | 42.3% |
| Q4 25 | -84.7% | 7.0% | ||
| Q3 25 | -140.7% | 1.9% | ||
| Q2 25 | -189.8% | -1.9% | ||
| Q1 25 | -245.8% | -2.4% | ||
| Q4 24 | -117.5% | 4.1% | ||
| Q3 24 | -152.1% | -67.4% | ||
| Q2 24 | -327.6% | -2.2% | ||
| Q1 24 | -16464.6% | -2.2% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | -135.3% | 0.5% | ||
| Q2 25 | -186.2% | -10.6% | ||
| Q1 25 | -235.5% | -4.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -142.7% | -68.5% | ||
| Q2 24 | -312.2% | -2.0% | ||
| Q1 24 | -15800.8% | -1.2% |
| Q4 25 | — | $9.50 | ||
| Q3 25 | — | $-0.86 | ||
| Q2 25 | $-0.33 | $-2.73 | ||
| Q1 25 | $-0.36 | $-1.66 | ||
| Q4 24 | $-0.24 | $-0.47 | ||
| Q3 24 | $-0.28 | $-12.79 | ||
| Q2 24 | $-0.34 | $-1.19 | ||
| Q1 24 | $-0.42 | $-1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $23.6M |
| Total DebtLower is stronger | — | $41.5M |
| Stockholders' EquityBook value | $698.6M | $111.4M |
| Total Assets | $913.2M | $407.7M |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $23.6M | ||
| Q3 25 | $300.8M | $26.7M | ||
| Q2 25 | $301.2M | $26.0M | ||
| Q1 25 | $359.7M | $31.0M | ||
| Q4 24 | $323.8M | $29.9M | ||
| Q3 24 | $397.5M | $20.0M | ||
| Q2 24 | $412.5M | $14.7M | ||
| Q1 24 | $356.2M | $18.7M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $698.6M | $111.4M | ||
| Q3 25 | $702.3M | $-26.3M | ||
| Q2 25 | $698.5M | $-21.7M | ||
| Q1 25 | $767.9M | $-13.5M | ||
| Q4 24 | $710.4M | $-8.3M | ||
| Q3 24 | $773.5M | $-2.7M | ||
| Q2 24 | $768.5M | $45.8M | ||
| Q1 24 | $680.0M | $51.4M |
| Q4 25 | $913.2M | $407.7M | ||
| Q3 25 | $904.9M | $406.9M | ||
| Q2 25 | $907.4M | $415.9M | ||
| Q1 25 | $966.7M | $421.5M | ||
| Q4 24 | $910.4M | $430.2M | ||
| Q3 24 | $991.1M | $412.5M | ||
| Q2 24 | $964.3M | $474.1M | ||
| Q1 24 | $869.8M | $477.7M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $3.2M |
| Free Cash FlowOCF − Capex | $-61.9M | $2.9M |
| FCF MarginFCF / Revenue | -71.3% | 3.1% |
| Capex IntensityCapex / Revenue | 10.7% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.07× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $21.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $3.2M | ||
| Q3 25 | $-78.7M | $9.5M | ||
| Q2 25 | $-67.4M | $932.0K | ||
| Q1 25 | $-103.7M | $9.1M | ||
| Q4 24 | $-73.3M | $-10.0M | ||
| Q3 24 | $-59.0M | $12.5M | ||
| Q2 24 | $-98.4M | $8.7M | ||
| Q1 24 | $-122.3M | $6.9M |
| Q4 25 | $-61.9M | $2.9M | ||
| Q3 25 | $-89.5M | $9.4M | ||
| Q2 25 | $-74.9M | $787.0K | ||
| Q1 25 | $-109.9M | $8.7M | ||
| Q4 24 | $-77.5M | $-10.3M | ||
| Q3 24 | $-61.3M | $12.4M | ||
| Q2 24 | $-98.9M | $8.5M | ||
| Q1 24 | $-126.5M | $6.6M |
| Q4 25 | -71.3% | 3.1% | ||
| Q3 25 | -132.7% | 10.5% | ||
| Q2 25 | -124.9% | 0.9% | ||
| Q1 25 | -222.8% | 10.1% | ||
| Q4 24 | -105.1% | -10.8% | ||
| Q3 24 | -104.6% | 14.0% | ||
| Q2 24 | -317.9% | 10.0% | ||
| Q1 24 | -17685.3% | 7.6% |
| Q4 25 | 10.7% | 0.3% | ||
| Q3 25 | 16.1% | 0.1% | ||
| Q2 25 | 12.4% | 0.2% | ||
| Q1 25 | 12.6% | 0.4% | ||
| Q4 24 | 5.7% | 0.2% | ||
| Q3 24 | 3.9% | 0.1% | ||
| Q2 24 | 1.4% | 0.2% | ||
| Q1 24 | 583.4% | 0.3% |
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
